{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.645","value":"0.02"},{"groupId":"OG001","spread":"2.721","value":"-0.25"}]}],"title":"Pain Severity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.077","value":"0.33"},{"groupId":"OG001","spread":"3.082","value":"-0.18"}]}],"title":"Pain Interference"}],"denoms":[{"counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"374"}],"units":"Participants"}],"description":"Pain severity (sensory dimension) and pain interference (reactive dimension, assessing the degree to which pain interferes with function) are measured using the Brief Pain Inventory- Short Form (BPI-SF).\n\nBPI-SF numeric rating scale goes from 0 (No pain) to 10 (Pain as bad as you can imagine).","dispersionType":"Standard Deviation","groups":[{"description":"Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG000","title":"E-Ld Cohort"},{"description":"Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG001","title":"Ld Cohort"}],"paramType":"MEAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From Baseline to End of Treatment (approximately 8 years)","title":"Mean Change From Baseline of Pain Severity Score and Pain Interference Score","type":"SECONDARY","unitOfMeasure":"Rating score"}